

Aventus Advises Windlas Healthcare on 51% Stake Acquisition by Cadila Healthcare

August 2018 • Mumbai



DEAL VALUE	Undisclosed
SERVICE	Mergers & Acquisitions
SECTOR	Healthcare

In a strategic move, Cadila Healthcare Limited (**CHL**), a leading Indian pharmaceuticals company said that it will be acquiring 51% stake in Dehradun-based Windlas Healthcare Private Limited (“**Windlas Healthcare**” or “**WHPL**”).

| Aventus Capital was the sole advisor to Windlas Healthcare for this transaction.

Windlas Healthcare has robust manufacturing infrastructure with a USFDA approved oral solids manufacturing facility. WHPL also has a dedicated R&D facility for formulations development and has developed four First-to-File ANDAs (Abbreviated New Drug Application) in the last two years. The strategic deal allows Cadila Healthcare to expand its manufacturing base.

Hitesh Windlass, Managing Director, Windlas Healthcare said, “We are excited to have Cadila Healthcare as a partner in our journey, particularly in regulated pharmaceutical markets. We believe that our capabilities in R&D, manufacturing and compliance, coupled with Cadila’s experience and reputation will be a great combination. The pharmaceuticals landscape in these markets is changing rapidly and this relationship will surely help the company achieve its planned objectives.”

Chintan Kothari, Executive Director - Healthcare Investment Banking at Aventus Capital said, “Windlas Healthcare has created a nimble organization with focused product development capabilities and strong manufacturing compliance standards. This partnership will allow Windlas Healthcare to continue to leverage the company’s strengths and benefit from the experience and track record of Cadila Healthcare to drive value creation for all stakeholders.

| About Aventus

The **Aventus Group (Aventus)** is a leading provider of financial services with an emphasis on customized solutions in the areas of Investment Banking, Wealth Management, Structured Credit Solutions and Alternative

Assets Management. Avendus relies on its extensive experience, in-depth domain understanding and knowledge of the regulatory environment, to offer customized solutions that enable clients to meet their strategic aspirations. Avendus Capital has consistently been ranked among the top financial advisors. It has a strong track record of cross-border transactions and has helped multiple clients benefit from opportunities across geographies.

Avendus's wide range of clients is testimony to its ability to serve its corporate clients throughout their life cycle – from growth stage funding to complex, large sized transactions later in the cycle.

Avendus Capital Inc. and **Avendus Capital (UK) Pvt. Ltd.** located in New York and London respectively are wholly owned subsidiaries offering M&A and Private Equity syndication services to clients in the respective regions.

For more information, please visit www.avendus.com

<p>Deal Release</p> <p>Contact: Lynette D'souza Tel: +91 9920847823 Email: lynette.dsouza@avendus.com</p>	<p>Avendus Capital Private Limited</p> <p>Regd. Office: 901, Platina, 9th Floor, Plot No. C-59, Bandra Kurla Complex, Bandra (E), Mumbai 400051</p>
---	---